
Quarterly ResultNov 16, 2026, 02:08 PM
60 Degrees Pharmaceuticals Reports Q3 Loss of $2.56M; Cash Runway Limited
AI Summary
60 Degrees Pharmaceuticals, Inc. filed its Form 10-Q for the period ending September 30, 2026, reporting a net loss of $2.56 million for the third quarter, an increase from the $2.32 million loss in the prior year's quarter. Product revenues also saw a decline. The company's financial position has weakened, with a significant decrease in cash and cash equivalents and an increase in total liabilities. Management has expressed substantial doubt about the company's ability to continue as a going concern, projecting that current cash will only sustain operations through early December 2026 without additional financing.
Key Highlights
- 60 Degrees Pharmaceuticals reported a net loss of $2.56 million for Q3 2026, compared to a net loss of $2.32 million in Q3 2025.
- For the nine months ended September 30, 2026, the net loss was $6.91 million, an increase from $5.93 million in the same period of 2025.
- Product revenues decreased to $233,235 in Q3 2026 from $437,602 in Q3 2025.
- Total assets decreased from $5.37 million as of December 31, 2025, to $3.09 million as of September 30, 2026.
- Total liabilities increased from $1.99 million as of December 31, 2025, to $2.34 million as of September 30, 2026.
- Cash and cash equivalents significantly decreased from $1.51 million at the end of 2025 to $306,191 at the end of Q3 2026.
- The company has substantial doubt about its ability to continue as a going concern, with cash projected to last only through early December 2026 without additional financing.
Price Impact
More from SXTP